Drug
Liposomal doxorubicin clinical trials
Also written ATI-0918.
A product of Doxorubicin; its studies count on that page too.
Keep track of what changes. Save the liposomal doxorubicin studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
237 studies that test it; most in 2005 (19)
| Year | Studies |
|---|---|
| 1997 | 2 |
| 1998 | 2 |
| 1999 | 4 |
| 2000 | 7 |
| 2001 | 4 |
| 2002 | 4 |
| 2003 | 9 |
| 2004 | 11 |
| 2005 | 19 |
| 2006 | 16 |
| 2007 | 11 |
| 2008 | 19 |
| 2009 | 13 |
| 2010 | 9 |
| 2011 | 5 |
| 2012 | 9 |
| 2013 | 4 |
| 2014 | 9 |
| 2015 | 8 |
| 2016 | 12 |
| 2017 | 8 |
| 2018 | 7 |
| 2019 | 12 |
| 2020 | 2 |
| 2021 | 5 |
| 2022 | 7 |
| 2023 | 5 |
| 2024 | 6 |
| 2025 | 4 |
| 2026 | 4 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 57 · Other 180
National Cancer Institute (NCI) (13) · M.D. Anderson Cancer Center (7) · Fudan University (7) · Merck Sharp & Dohme LLC (6) · Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (6) · H. Lee Moffitt Cancer Center and Research Institute (5) · Gynecologic Oncology Group (5) · Sun Yat-sen University (4)
Often tested with
Tested in the same studies.
Bortezomib (23) · Cyclophosphamide (19) · Dexamethasone (19) · Paclitaxel (17) · Carboplatin (16) · Bevacizumab (15) · Docetaxel (11) · Trastuzumab (8)
Related medicines
As reviewed, each with the page that says it.
- A dosage form of Doxorubicin
Studies
Open first, then newest update. How each study uses liposomal doxorubicin is read from its arms, and is right about nine times in ten.
Testing it · 237
- Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced SarcomaRecruitingPhase 1National Cancer Institute (NCI)NCT05711615Written as Pegylated Liposomal Doxorubicin Hydrochloride
- Natural History Study of the KSHV Inflammatory Cytokine Syndrome (KICS)RecruitingPhase 2National Cancer Institute (NCI)NCT01419561Written as Liposomal Doxorubicin
- Metastatic Ewing's Trial Testing Schedule Enhancement to Improve OutcomesRecruitingPhase 1H. Lee Moffitt Cancer Center and Research InstituteNCT07194044Written as Liposomal doxorubicin
- Disulfiram With Copper Gluconate and Liposomal Doxorubicin in Treatment-Refractory SarcomasRecruitingPhase 1Case Comprehensive Cancer CenterNCT05210374Written as Liposomal Doxorubicin (Doxil)
- APG-2449 Monotherapy or in Combination With PLD in Patients With Platinum-resistant Recurrent OC or Advanced STRecruitingPhase 1Ascentage Pharma Group Inc.NCT06687070Written as PLD
- Pegylated Liposomal Doxorubicin (PLD) Versus Active Surveillance for Advanced Soft Tissue Sarcoma Patients Who Had Controlled Disease After Standard Anthracycline-based Treatment (MELODY)RecruitingPhase 2National Health Research Institutes, TaiwanNCT06981637Written as Pegylated liposomal doxorubicin
- Pyrotinib Plus Trastuzumab and Chemotherapy for HER2-Positive Early Breast CancerRecruitingPhase 2Hebei Medical University Fourth HospitalNCT07635342Written as pegylated liposomal doxorubicin hydrochloride
- The Combination of Radiotherapy, Chemotherapy and Immunotherapy in High-Risk Localized Soft Tissue SarcomaRecruitingPhase 1/2Fudan UniversityNCT05774275Written as Pegylated Liposomal Doxorubicin
- Doxorubicin Hydrochloride Liposome Combined With Irinotecan (AI Regimen) Versus VIT Regimen in the Treatment of Relapsed and Refractory Pediatric Rhabdomyosarcoma: a Prospective, Open-label, Randomized Controlled, Multicenter, Phase II Clinical StudyRecruitingPhase 2Sun Yat-sen UniversityNCT05457829Written as Doxorubicin Hydrochloride Liposome+Irinotecan
- Phase II Study of Ultrasound and ctDNA Guided Neoadjuvant Systemic Therapy for Patients With HER2-positive Early Breast Cancer (UC HER Trial)Not yet recruitingPhase 2National Taiwan University HospitalNCT07565324Written as Lipo-Dox®
- Tamoxifen and Pegylated Liposomal Doxorubicin for the Treatment of Patients With Metastatic or Inoperable, Locally Advanced Triple Negative Breast CancerRecruitingPhase 2Roswell Park Cancer InstituteNCT06434064Written as Pegylated Liposomal Doxorubicin Hydrochloride
- Study of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast CancerRecruitingPhase 2SCRI Development Innovations, LLCNCT05748834Written as Doxil
- Combination Therapy for Recurrent Ovarian CancerRecruitingPhase 1/2Sham Sunder KakarNCT05610735Written as DOXIL
- Paclitaxel and Pegylated Liposomal Doxorubicin for Treatment of HIV-related Kaposi SarcomaNot yet recruitingPhase 3AIDS Malignancy ConsortiumNCT05411237Written as Pegylated liposomal doxorubicin
- IO Combined With AI as First-line Treatment for Patients With Soft Tissue Sarcoma(TAIS)RecruitingPhase 2Fudan UniversityNCT06849986Written as Tislelizumab+liposomal doxorubicin+ifosfamide
- Pegylated Liposomal Doxorubicin Plus Adebrelimab With or Without Mirabegron in Relapsed Ovarian CancerRecruitingPhase 2/3Obstetrics & Gynecology Hospital of Fudan UniversityNCT06791460Written as Pegylated liposomal doxorubicin plus adebrelimab with mirabegron
- First-line Treatment of Advanced/unresectable DDLPSNot yet recruitingPhase 2Fudan UniversityNCT06694324Written as Liposomal Doxorubicin (Doxil)
- Neoadjuvant Treatment Pegylated Liposomal Doxorubicin Plus Cyclophosphamide Sequential Docetaxel Plus Trastuzumab and Pertuzumab Versus Docetaxel Plus Carboplatin Combined With Trastuzumab and Pertuzumab in HER-2 Positive Breast CancerRecruitingPhase 3Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNCT05159193Written as pegylated liposomal doxorubicin (PLD)
- The Effectiveness and Safety of XELOX and Tislelizumab + PLD for Resectable Gastric Cancer (LidingStudy)RecruitingPhase 2Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineNCT05536102Written as PLD
- To Evaluate the Cardiac Safety of Pegylated Liposomal Doxorubicin Concurrently Plus Trastuzumab and Pertuzumab in the Adjuvant Setting for Early-stage HER-2-positive Breast Cancer: a Multicenter, Randomized Controlled Clinical StudyRecruitingNot applicableShanghai Pudong HospitalNCT05656079Written as Pegylated liposomal doxorubicin
See all 237 studies that test liposomal doxorubicin →
Given in every arm · 72 — liposomal doxorubicin is usual care beside what is tested
- Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin LymphomaRecruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT03618550Written as liposomal doxorubicin
- Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ TrialRecruitingPhase 2National Cancer Institute (NCI)NCT03907475Written as Pegylated Liposomal Doxorubicin Hydrochloride
- ctDNA-Guided Therapy for Relapsed/Refractory Hodgkin LymphomaRecruitingPhase 2Michael Spinner, MDNCT07021989Written as Liposomal Doxorubicin
- SBRT Combined With Reduced-Dose Anthracycline Chemotherapy and Toripalimab as Neoadjuvant Therapy for Localized High-Risk Undifferentiated Pleomorphic SarcomaNot yet recruitingPhase 2Tianjin Medical University Cancer Institute and HospitalNCT07817095Written as Liposomal doxorubicin
- A Study of BL-M08D1 in Combination With Immunochemotherapy in Patients With Diffuse Large B-Cell LymphomaNot yet recruitingPhase 1/2Sichuan Baili Pharmaceutical Co., Ltd.NCT07818499Written as Doxorubicin Hydrochloride Liposome
- Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian CancerRecruitingPhase 2Regeneron PharmaceuticalsNCT06787612Written as PLD
- A Clinical Study of SHR-A1811 Combined With Chemotherapy for Platinum Sensitive Recurrent Ovarian CancerRecruitingPhase 1/2Suzhou Suncadia Biopharmaceuticals Co., Ltd.NCT06840002Written as Doxorubicin hydrochloride liposome injection
- CD40 Agonist, Flt3 Ligand, and Chemotherapy in HER2 Negative Breast CancerRecruitingPhase 1University of Texas Southwestern Medical CenterNCT05029999Written as PLD Chemotherapy
- A Study of Azenosertib (ZN-c3) in Patients With Ovarian CancerRecruitingPhase 1K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, IncNCT04516447Written as Pegylated liposomal doxorubicin
- Corticosteroids for Doxorubicin Liposome-Induced Hand-Foot-Skin ReactionsRecruitingPhase 3Fudan UniversityNCT07362914Written as Doxorubicin hydrochloride liposome injection
- IN10018 in Combination With Pegylated Liposomal Doxorubicin (PLD) vs. Placebo in Combination With PLD for the Treatment of Platinum-resistant Recurrent Ovarian CancerRecruitingPhase 2InxMed (Shanghai) Co., Ltd.NCT06014528Written as Pegylated Liposomal Doxorubicin
- ATG-010(Selinexor) in Combination With Chemotherapy in RRMMRecruitingPhase 2Chunyan Sun, MDNCT04877275Written as Pegylated liposomal doxorubicin
- Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal CancerActive, not recruitingPhase 2/3National Cancer Institute (NCI)NCT02839707Written as Pegylated Liposomal Doxorubicin Hydrochloride
- A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid TumorsCompletedPhase 1Toray Industries, IncNCT03872947Written as PLD
- Combination Chemotherapy and Bevacizumab With the NovoTTF-100L(P) System in Treating Participants With Advanced, Recurrent, or Refractory Hepatic Metastatic CancerTerminatedPhase 1M.D. Anderson Cancer CenterNCT03203525Written as Pegylated Liposomal Doxorubicin Hydrochloride
- Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)Active, not recruitingPhase 3Merck Sharp & Dohme LLCNCT04895358Written as liposomal doxorubicin
- 9-ING-41 in Patients With Advanced CancersActive, not recruitingPhase 2Actuate Therapeutics Inc.NCT03678883Written as Doxorubicin.
- Pyrotinib Plus Neoadjuvant Chemotherapy in HR+/HER2-, HER4-High Breast CancerActive, not recruitingPhase 2Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNCT04872985Written as Doxorubicin Hydrochloride Liposome Injection
- Atezolizumab Combined with Immunogenic Chemotherapy in Patients with Metastatic Triple-negative Breast CancerCompletedPhase 2Oslo University HospitalNCT03164993Written as Pegylated liposomal doxorubicin
- Phase IIb Study Evaluating Immunogenic Chemotherapy Combined with Ipilimumab and Nivolumab in Breast CancerCompletedPhase 2Oslo University HospitalNCT03409198Written as Pegylated liposomal doxorubicin
Showing 20 of 72.
As the comparator · 43 — what is tested is compared with liposomal doxorubicin
- A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)RecruitingPhase 3Merck Sharp & Dohme LLCNCT07060807Written as Pegylated liposomal doxorubicin
- A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003).RecruitingPhase 1/2Merck Sharp & Dohme LLCNCT06843447Written as Pegylated liposomal doxorubicin
- Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and Bevacizumab) for Treating Recurrent Platinum-Sensitive Ovarian Cancer After PARP Inhibitor Maintenance TherapyRecruitingPhase 2National Cancer Institute (NCI)NCT07504588Written as Pegylated Liposomal Doxorubicin Hydrochloride
- A Clinical Trial of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab in Participants With Ovarian Cancer Who Have Progressed During Treatment With PARP-inhibitors Treatment on First Line Maintenance (MK-5909-008/ENGOT-ov107/GOG-3142 / REJOICE-Ovarian05)RecruitingPhase 3Merck Sharp & Dohme LLCNCT07743164Written as Pegylated liposomal doxorubicin (PLD)
- A Study to Investigate Mocertatug Rezetecan Compared With Standard of Care in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01)RecruitingPhase 3GlaxoSmithKlineNCT07286266Written as Pegylated liposomal doxorubicin (PLD)
- A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)RecruitingPhase 3Merck Sharp & Dohme LLCNCT06312176Written as Liposomal doxorubicin
- A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian CancerRecruitingPhase 3Eli Lilly and CompanyNCT07213804Written as Pegylated liposomal doxorubicin (PLD)
- A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian CancerRecruitingPhase 3Verastem, Inc.NCT06072781Written as Pegylated liposomal doxorubicin
- Study to Assess the Efficacy and Safety of Rina-S With or Without Bevacizumab Compared to Investigator's Choice of Platinum-based Chemotherapy With or Without Bevacizumab as Second-line Treatment in Participants With Recurrent Platinum-sensitive Ovarian CancerRecruitingPhase 3GenmabNCT07564141Written as PLD
- An Extension Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer in ChinaRecruitingPhase 3GenmabNCT07604766Written as Pegylated liposomal doxorubicin (PLD)
- A Study to Investigate Mocertatug Rezetecan With Bevacizumab Compared With Platinum Doublet With Bevacizumab in Participants With Platinum-sensitive Ovarian Cancer (BEHOLD-Ovarian02)RecruitingPhase 3GlaxoSmithKlineNCT07684612Written as Pegylated liposomal doxorubicin (PLD)
- Trastuzumab Rezetecan and Carboplatin ± Bevacizumab Versus Investigator's Choice Chemotherapy in Patients With Platinum-sensitive Recurrent Ovarian CancerNot yet recruitingPhase 2Sun Yat-sen UniversityNCT07776171Written as Carboplatin + pegylated liposomal doxorubicin
- A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube CancerRecruitingPhase 2/3Daiichi SankyoNCT06161025Written as PLD
- AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian CancerRecruitingPhase 3AstraZenecaNCT07218809Written as Pegylated liposomal Doxorubicin (PLD)
- A Study Comparing BL-M07D1 With Physician's Choice of Chemotherapy in Patients With HER2-Expressing Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal CancerNot yet recruitingPhase 3Sichuan Baili Pharmaceutical Co., Ltd.NCT07545460Written as Liposomal Doxorubicin
- A Three-arm Randomized Phase II Study of Dostarlimab Alone or With Bevacizumab Versus Nonplatinum Chemotherapy in Recurrent Gynecological Clear Cell Carcinoma: DOVE (APGOT-OV7/ ENGOT-ov80 Study)RecruitingPhase 2Yonsei UniversityNCT06023862Written as Pegylated liposomal doxorubicin
- A Study of SHR-A1811 in Subjects With Ovarian CancerRecruitingPhase 3Jiangsu HengRui Medicine Co., Ltd.NCT06828354Written as Doxorubicin Hydrochloride Liposome Injection
- Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic AgentsActive, not recruitingPhase 2National Cancer Institute (NCI)NCT04739800Written as Pegylated Liposomal Doxorubicin Hydrochloride
- Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation DetectedTerminatedPhase 3Novartis PharmaceuticalsNCT04729387Written as Pegylated liposomal doxorubicin (PLD)
- Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian CancerActive, not recruitingPhase 2/3National Cancer Institute (NCI)NCT02502266Written as Pegylated Liposomal Doxorubicin Hydrochloride
Showing 20 of 43.
Codes
What other systems call liposomal doxorubicin · ClinicalTrials.gg INT004851
- MeSH (NLM) C506643liposomal doxorubicinOne source ClinicalTrials.gov
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C506643 | liposomal doxorubicin | One source ClinicalTrials.gov |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.